Nouveau patient au Centre du Cancer et d'hématologie ? Appelez le 02 764 12 00

Liste des études en cours

 

 

Tumeurs Colo-rectales

 

An Open-Label, Four-Part, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibito GSK1120212, BRAF Inhibito GSK2118436 and the anti-EGFR Antibody Panitumuma in Combination in Subjects with BRAF-mutation V600E Positive Colorectal Cancer and in subjects with CRC with secondary resistance to prior anti-EGFR Therapy. MEK116833

Sponsor: /
Principal Investigator: Prof. Y. Humblet
Contact: C. Szablonski 02/764 42 21

 

Randomized Phase 2 study comparing pathological responses observed on colorectal cancer metastases resected after preoperative treatment combining Bevacizumab with FOLFOX or FOLFIRI. BEV-ONCO2012

Sponsor: /
Principal Investigator: Dr. M. Van Den Eynde
Contact: F. Masquelier 02/764 35 86

 

A Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer. Xbiotech

Sponsor: /
Principal Investigator: Dr. M. Van Den Eynde
Contact: F. Masquelier 02/764 35 86

 

An open-label, multicenter, dose escalation, phase IB study with expansion phase to investigate the safety, pharmacokinetics, pharmacodynamics and therapeutic activity of emactuzumab and RO7009789 administrered in combination in patients with advanced solid tumors

Partie I : escalation phase : sein triple négatif, ovaire, pancréas, estomac, colorectal, mélanome, mésothéliome.

Partie II : expansion phase : colorectal, mélanome, BP29427

Sponsor: /

Principal Investigator:  Prof. JP.Machiels

Contact:V.Decroës 02/764 42 30

 

A phase Ib, open-label, multi-center study to chracterize the safety, tolerability and pharmacodynamics (PD) of PDR001 in combination with CJM112, EGF816, ILARIS(canakimumab) or Mekinist( trametinib) : TNBC/NSCLC- adenocarcinoma- CRC. PDR001X2103

Sponsor: /

Principal Investigator: Prof. JP.Machiels

 

A phase III, open-label, multicenter, three-arm, randomized study to investigate the efficacy and safety of cobimetinib plus atezolizumab and atezolizumab monotherapy vs. Regorafenib i npatients with previously treated unresectable locally advanced or metastatic colorectal adenocarcinoma. GO30182

Sponsor: /

Principal Investigator: Dr M. Van den Eynde

Contact:F.Masquelier 02/764 35 86

 

An open-label early access phase IIIb study of trifluridine/tipiracil (S95005/TAS-102) in patients with a pretreated metastatic colorectal cancer. CL3-95005-004 (Lonsurf) 

Sponsor: /

Principal Investigator: Dr M. Van den Eynde

Contact:F.Masquelier 02/764 35 86

 

_________________________________________________________

 

Tumeurs de l'appareil urinaire


Cancer de la prostate

 

A Multinational, Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Enzalutamide in Patients With Non-metastatic Castration-Resistant Prostate Cancer. PROSPER

Sponsor: /
Principal Investigator: Prof. B. Tombal
Contact: A-M. Van Thienen 02/764 35 45 / V. Butoescu 02/764 35 46

 

A Randomized, Double Blind, Multicenter, Parallel-Group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men with Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line chemotherapy. SP005/Sotio

Sponsor: /
Principal Investigator: Prof. B. Tombal
Contact: A. Van Thienen 02/764 35 45 / V. Butoescu 02/764 35 46


Etude prospective de phase III ,randomisée,d'évaluation de l'association d'un traitement hormonal avec ou sans radiothérapie avec ou sans abiraterone et prednisone chez les patients présentant un cancer de prostate métastatique hormono-naïf. EORTC1201 /PEACE 1
Sponsor: EORTC
Principal Investigator: Prof. B. Tombal
Contact: A. Van Thienen 02/764 35 45 / V. Butoescu 02/764 35 46

 

A randomized, open label, multicenter study of Cabazitaxel versus an AR-targeted agent (abiraterone or enzalutamide) in mCRPC patients previously treated with Docetaxel and who rapidly failed a prior AR-targeted agent (CARD). CARD / LPS14201

Sponsor: /

Principal Investigator: Prof. JP.Machiels

Contact:A-M. Van Thienen 02/764 35 45 / V. Butoescu 02/764 35 46

 

-PEACE III : A Randomized multicenter phase III trial, comparing enzalutamide vs. a combination of Ra223 and enzalutamide in asymptomatic or mildly symptomatic chemotherapy naïve castration resistant prostate cancer patients metastatic to bone (study acronym: PEACE 3) EORTC-1333-GUCG

Sponsor: /

Principal Investigator: Prof. JP.Machiels

Contact:A-M. Van Thienen 02/764 35 45 / V. Butoescu 02/764 35 46

 

REASSURE, Radium-223 alpha Emitter Agent in Safety Study in mCRPC popUlation for long-teRm Evaluation. BAY16913 REASSURE

Sponsor: /

Principal Investigator: Prof. B. Tombal

Contact:A-M. Van Thienen 02/764 35 45 / V. Butoescu 02/764 35 46

 

PEACE II: A randomized Phase III, factorial design, of cabazitaxel and pelvic radiotherapy in patients with localized prostate cancer and high-risk features of relapse. GETUG-AFU23

Sponsor: /

Principal Investigator: Prof. JP.Machiels, Prof. L. Renard, Prof. B. Tombal

Contact:A-M. Van Thienen 02/764 35 45 / V. Butoescu 02/764 35 46

 

A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy. ATLAS

Sponsor: /

Principal Investigator: Prof. L. Renard, Prof. B. Tombal

Contact:A-M. Van Thienen 02/764 35 45 / V. Butoescu 02/764 35 46

 

First-human, dose-escalating safety study of tissue factor specific antibody drug conjugate (HUMAX®-TF-ADC) in patient with locally advanced and/or metastatic solid tumors known to express tissue factor: Col / endomètre / ovaire (waiting list) / vessie /prostate / poumon / œsophage + ORL. GEN701

Sponsor: /

Principal Investigator: Prof. JP.Machiels

Contact:I. Beaufay 02/764 42 04

 

A Phase 1b/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 as a Single Agent and In Combination with Enzalutamide in Subjects with Metastatic Castrate-Resistant Prostate Cancer. GS-US-350-1604 

Sponsor: /

Principal Investigator: Prof. L. Renard, Prof. B. Tombal

Contact:A-M. Van Thienen 02/764 35 45 / V. Butoescu 02/764 35 46

(En attente accord CE) 

 

Cancer de la vessie

 

A phase 2, two-arm multicenter, open-label study to determine the efficacy and the safety of two different dose regimens of a pan-FGFR Thyrosine kinase inhibitor JNJ-42756493 in subjects with metastatic or surgically unresectable urothelial cancer with FGFR genomic alteration. BLC2001
Sponsor: /
Principal Investigator: Prof. J.P. Machiels
Contact: B. Vanderelst 02/764 42 99

 

A Phase 3,Randomized,Double-Bind,Placebo-Controlled Study of Ramucirumab plus Docetaxel Versus Placebo plus Docetaxel in patients with Locally Advanced or Unresectable or Metastatic Urothelial Carcinoma Who Progressed on or After Platinium-Based Therapy. I4T-MC-JVDC
Sponsor: /
Principal Investigator: Prof. JP. Machiels
Contact: A-M. Van Thienen 02/764 35 45 / V. Butoescu 02/764 35 46

 

phase III, open-label, multicenter, randomized study of mpdl3280a (anti -pd-l1 antibody) versus observation as adjuvant therapy in patients withpd-l1 selected, high-risk muscle-invasive bladder cancer after cystectomy. IMvigor
Sponsor: /
Principal Investigator: Prof. JP. Machiels
Contact: A-M. Van Thienen 02/764 35 45 / V. Butoescu 02/764 35 46

 

A Phase III, Randomized, Open-label, Controlled, Multi Center, Global Study of First-Line MEDI4736 Monotherapy and MEDI4736 in Combination with Tremelimumab Versus Standard of Care Chemotherapy in Patients with Unresectable Stage IV Urothelial Bladder Cancer. DANUBE

Sponsor: /

Principal Investigator: Prof. JP.Machiels

Contact:A-M. Van Thienen 02/764 35 45 / V. Butoescu 02/764 35 46

 

First-human, dose-escalating safety study of tissue factor specific antibody drug conjugate (HUMAX®-TF-ADC) in patient with locally advanced and/or metastatic solid tumors known to express tissue factor : Col / endomètre / ovaire (waiting list) / vessie /prostate / poumon / œsophage + ORL. GEN701

Sponsor: /

Principal Investigator: Prof. JP.Machiels

Contact:I. Beaufay 02/764 42 04

 

A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab with or without Platinum-Based Combination Chemotherapy versus Chemotherapy in Subjects with Advanced or Metastatic Urothelial Carcinoma. MK3475-361

Sponsor: /

Principal Investigator: Prof. JP.Machiels

Contact:A-M. Van Thienen 02/764 35 45 / V. Butoescu 02/764 35 46

(En attente accord CE) 

 

Cancer du rein


A proof of concept study to evaluate the use of metabolomics and lipidomics in predicting toxicity and efficacy of sunitinib in patients with metastatic clear cell renal cell carcinoma. Metasun

Sponsor: /
Principal Investigator: Prof. J.P. Machiels

Contact: V. Butoescu 02/764.35.46

 

A phase 3, multinational, randomized, open-label, parallel-arm study of avelumab (msb0010718c) in combination with axitinib (inlyta®) versus sunitinib (sutent®) monotherapy in the first-line treatment of patients with advanced renal cell carcinoma. B9991003

Sponsor: /

Principal Investigator: Prof. JP.Machiels

Contact:A-M. Van Thienen 02/764 35 45 / V. Butoescu 02/764 35 46

(En attente accord CE) 


Germ Cells Tumor

 

A Randomized phase III trial comparing conventional-dose chemotherapy using paclitaxel, ifosfamide, and cisplatin (TIP) with high dose chemotherapy using mobilizing paclitaxel plus ifosfamide followed by Highdose carboplatin and etoposide (TI-CE) as first salvage treatment in relapsed or refractory germ cell tumors.EORTC1407/TIGER
Sponsor: /
Principal Investigator: Prof. JP. Machiels
Contact: A-M. Van Thienen 02/764 35 45 / V. Butoescu 02/764 35 46

_________________________________________________________

 

Tumeurs de l'oesophage et de l'estomac

 

A Phase III Randomized, Double-Blind, Placebo-Controlled Clinical Trial of BBI608 plus Weekly Paclitaxel vs. Placebo plus Weekly Paclitaxel in Adult Patients with Advanced, Previously Treated Gastric and Gastro-Esophageal Junction Adenocarcinoma. BBI608

Sponsor: /
Principal Investigator: Prof. M. Van Den Eynde
Contact: F. Masquelier 02/764 35 86

 

A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monotherapy and in Combination with Cisplatin+5-Fluorouracil versus Placebo+Cisplatin+5-Fluorouracil as First-Line Treatment in Subjects with Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma. Merk

Sponsor: /

Principal Investigator: Prof. M. Van den Eynde

Contact: F.Masquelier 02/764 35 86

 

Randomized, double-blind, phase 3 study evaluating tas-102 plus best supportive care (bsc) versus placebo plus bsc in patients with metastatic gastric cancer refractory to standard treatments.TAS

Sponsor: /

Principal Investigator: Prof. M. Van den Eynde

Contact: F.Masquelier 02/764 35 86

 

A Randomized, Multicenter, Double Blind, Phase III Study of Adjuvant Nivolumab or Placebo in Subjects with Resected Esophageal, or Gastroesophageal Junction Cancer. CA209-577

Sponsor: /

Principal Investigator: Prof. M. Van den Eynde

Contact: F.Masquelier 02/764 35 86

 

A phase 3 open-label, multicenter trial of avelumab (MSB0010718C) as a third-line treatment of unresectable, recurrent or metastatic gastric or gastroesophageal junction adenocarcinoma.Javelin Gastric 300

Sponsor: /

Principal Investigator: Prof. M. Van den Eynde

Contact: F.Masquelier 02/764 35 86

 

Non- comparative, two cohort, single arm, open-label, phase 1/2 study of nivolumab (BMS-936558) in subjects with virus-positive and virus -negative solid tumors

2 cohortes :

- Adjuvante : reste: Estomac EBV + CA209-358

Sponsor: /

Principal Investigator:  Prof. JP.Machiels

Contact:V.Decroës 02/764 42 30

 

First-human, dose-escalating safety study of tissue factor specific antibody drug conjugate (HUMAX®-TF-ADC) in patient with locally advanced and/or metastatic solid tumors known to express tissue factor : GEN701

Sponsor: /

Principal Investigator: Prof. JP.Machiels

Contact:I. Beaufay 02/764 42 04

 

An open-label, multicenter, dose escalation, phase IB study with expansion phase to investigate the safety, pharmacokinetics, pharmacodynamics and therapeutic activity of emactuzumab and RO7009789 administrered in combination in patients with advanced solid tumors

Partie I : escalation phase : sein triple négatif, ovaire, pancréas, estomac, colorectal, mélanome, mésothéliome.

Partie II : expansion phase : colorectal, mélanome, BP29427

Sponsor: /

Principal Investigator:  Prof. JP.Machiels

Contact:V.Decroës 02/764 42 30

 

A phase I/IIa study of BMS 986148, a mesothelin directed antibody drug conjugate, in subjects with selected advanced solid tumors: cancer du pancréas, cancer des ovaires, cancer du poumon non à petites cellules [CPNPC], cancer de l’estomac ou mésothéliome. CA008-002

Sponsor: /

Principal Investigator:  Prof. JP.Machiels

Contact: C. Szablonski 02/764 42 21

 

_________________________________________________________

 

Tumeurs de la peau - Clinique du mélanome

 

Cutaneous Melanoma

 

Clinical Trial of Nivolumab (BMS-936558) Combined with Ipilimumab Followed by Nivolumab Monotherapy as First-Line Therapy of Subjects with Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma. Checkmate 401

Sponsor: /
Principal Investigator: Prof. JF. Baurain

Contact: K. Amann 02/764 35 14


A phase I, open-label, multi-centre, multi-dose, dose escalation study of LTX-315 as monotherapy or in combination witheither ipilimumab or pembrolizumab in patients with transdermally accessible tumours. C12-315-03

Sponsor: Lytix biopharma
Principal Investigator: Prof. JF. Baurain

Contact: B. Vanderelst 02/764 42 99

 

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Pembrolizumab (MK-3475) in Combination With Epacadostat or Placebo in Subjects with Unresectable or Metastatic melanoma (Keynote 252/ Echo 301) 

Sponsor: /

Principal Investigator: Prof. JF. Baurain

Contact:K. Amann 02/764 35 14

 

A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma. Masterkey-265

Sponsor: /

Principal Investigator: Prof. JF. Baurain

Contact: L. Favaretto 02/764 35 13

 

An open-label, multicenter, dose escalation, phase IB study with expansion phase to investigate the safety, pharmacokinetics, pharmacodynamics and therapeutic activity of emactuzumab and RO7009789 administrered in combination in patients with advanced solid tumors

Partie I : escalation phase : sein triple négatif, ovaire, pancréas, estomac, colorectal, mélanome, mésothéliome.

Partie II : expansion phase : colorectal, mélanome, BP29427

Sponsor: /

Principal Investigator:  Prof. JP.Machiels

Contact:V.Decroës 02/764 42 30

 

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications : melanome(après anti PD1/PDL1 et après anti-BRAF). EMR200647-001

Sponsor: /

Principal Investigator: Prof. JP.Machiels

Contact:I. Beaufay 02/764 42 04

 

_________________________________________________________

 

Tumeurs de la tête et du cou

 

A blind randomized multicenter study of accelerated fractionated chemo-radiotherapy with or without the hypoxic cell radiosensitizer nimorazole(Nimoral), using a 15-gene signature for hypoxia in the treatment of HPV/p16 negative squamous cell carcinoma of the head and neck. EORTC1219

Sponsor:/

Principal Investigator: Prof.V. Grégoire

Contact: G. Moreau 02/764 12 74

 

A phase II study exploring the safety and efficacy of nintedanib (BIBF1120) as second line therapy for patients with either differentiated or medullary thyroid cancer progressing after first line therapy. EORTC1209
Sponsor: EORTC
Principal Investigator: Dr. F. Cornelis
Contact: G. Moreau 02/764 12 74


Phase I study study of LEE011 plus cetuximab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. CETLEE011

Sponsor:/
Principal Investigator:Prof. JP. Machiels

Contact: A. Gillain 02/764 54 70

 

A Multicenter, Randomized, Double-blind Phase 2 Trial of Lenvatinib (E7080) in Subjects With 131I-Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 20 mg or 14 mg Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile. EISAI 211

Sponsor: /

Principal Investigator: Dr. F. Cornelis 

Contact: G. Moreau 02/764 12 74

 

A Phase III Randomized, Open-label, Multi-center, Global Study of MEDI4736 in Combination with Tremelimumab versus Standard of Care (EXTREME) in the Treatment of First-line Recurrent or Metastatic Squamous Cell Head and Neck Cancer Patients. Kestrel

Sponsor: /

Principal Investigator: Prof. JP Machiels

Contact: G. Moreau 02/764 12 74

 

A randomized phase II study to evaluate the efficacy and safety of chemotherapy (CT) vs androgen deprivation therapy (ADT) in patients with recurrent and/or metastatic, androgen receptor (AR) expressing, salivary gland cancer (SGCs). EORTC 1206

Sponsor: EORTC

Principal Investigator: Prof. JP Machiels

Contact: G. Moreau 02/764 12 74

 

A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Monotherapy and MEDI4736 in Combination with Tremelimumab Versus Standard of Care Therapy in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck. EAGLE

Sponsor: /

Principal Investigator: Prof. JP Machiels 

Contact: G. Moreau 02/764 12 74

 

A phase 1b/2, open-label, multi-center study assessing the safety, tolerability, pharmacokinetics and preliminary anti tumor activity of MEDI4736 in combination with AZD9150 or AZD5069in patients with advanced solid malignancies and subsequently comparing AZD9150 and AZD5069 both as monitherapy and in combination with MEDI4736 as second line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the H&N. D5660C00004

Sponsor: /

Principal Investigator:  Prof. JP.Machiels

Contact: C. Szablonski 02/764 42 21

 

Non- comparative, two cohort, single arm, open-label, phase 1/2 study of nivolumab (BMS-936558) in subjects with virus-positive and virus -negative solid tumors 

2 cohortes :

- Néo-adjuvante (2cures de Nivo) : SCCHN (HPV+ et -), Adjuvante : reste : SCCHN HPV +, CA209-358

Sponsor: /

Principal Investigator:  Prof. JP.Machiels

Contact:V.Decroës 02/764 42 30


_________________________________________________________

 

Tumeurs du sein

ER+HER2-

 

The PEARL study. PET imaging as a biomarker of Everolimus added value in hormone refractory postmenopausal woman. PEARL
Sponsor: /
Principal Investigator: Prof. F. Duhoux
Contact: N. Blondeel 02/764 42 14

 

Randomized, double-blind,multicentric phase III trial evaluating the safety and benefit of adding Everolimus to adjuvant hormone therapy in women with poor prognosis, ER+ and HER2- primary breast cancer who remain free of disease after receiving 1 year of adjuvant hormone therapy. UNIRAD

Sponsor: /
Principal Investigator: Prof. F. Duhoux
Contact: N. Blondeel 02/764 42 14

 

A phase Ib/II randomized study of BI836845 in combination with exemestane and everolimus versus exemestane and everolimus alone in women with locally advanced or metastatic breast cancer. Bl1280.4

Sponsor: /
Principal Investigator: Prof. F. Duhoux
Contact: C. Szablonski 02/764 42 21

 

Open-label, randomized, multicenter, international comparative exploratory phase II study, comparing 3 FEC-3 Docetaxel chemotherapy to letrozole + palbociclib combination as neoadjuvant treatment of stage II-IIIA PAM 50 ROR-defined low or intermediate risk Luminal breast cancer, in postmenopausal women. NEOPAL

Sponsor: /
Principal Investigator: Prof. F. Duhoux
Contact: N. Blondeel 02/764 42 14 / A. Mitton 02/764 42 24

 

A multicentre, Phase IIb, randomised, double blind, placebo-controlled study in hormone receptor-positive metastatic breast carcinoma patients receiving IMP321 (LAG-3Ig fusion protein) or placebo as adjunctive to a standard chemotherapy treatment regimen of paclitaxel. AIPAC (Active Immunotherapy PAClitaxel)

Sponsor: /

Principal Investigator:  Prof. JP.Machiels

Contact:V.Decroës 02/764 42 30 / N. Blondeel 02/764 42 14 / E. Villar 02/764 42 14

 

A Multicentre Phase 2 Study of SFX-01 Treatment and Evaluation in Patients with Estrogen Receptor (ER) Positive and Human Epidermal Growth Factor Receptor 2 (HER2) Negative Metastatic Breast Cancer Progressing on either an Aromatase Inhibitor (AI) or Tamoxifen or Fulvestrant. EVGEN-STEM

Sponsor: /

Principal Investigator: Prof. F. Duhoux

Contact: N. Blondeel / E. Villar 02/764 42 14


BRCA+

 

A Phase 3 Randomized, Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the PARP Inhibitor Veliparib (ABT-888) in HER2-Negative
Metastatic or Locally Advanced Unresectable BRCA-Associated Breast Cancer. Veliparib
Sponsor: Abbvie
Principal Investigator: Prof. F. Duhoux
Contact: N. Blondeel 02/764 42 14 

 

A randomised, double-blind, parallel group, placebo-controlled multicentre Phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy. OLYMPIA

Sponsor: Astrazeneca
Principal Investigator: Prof. F. Duhoux
Contact: N. Blondeel 02/764 42 14

 

A phase III, randomized, open label, multicenter, controlled trial of niraparib versus physician’s choice in previously-treated, HER2 negative, germline BRCA mutation-positive breast cancer patients. BRAVO

Sponsor: Tesaro
Principal Investigator: Prof. F. Duhoux
Contact: N. Blondeel 02/764 42 14 

 

Triple negative

 

A randomized, double-blind, placebo-controlled Phase 2 Study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer. FRIDA

Sponsor: /
Principal Investigator: Prof. F. Duhoux
Contact: N. Blondeel 02/764 42 14 

 

A randomized phase II study of MCS110 combined with carboplatin and gemcitabine in advanced Triple Negative Breast Cancer (TNBC). NOVARTIS - CMCS110Z2201

Sponsor: /

Principal Investigator: Prof. F. Duhoux

Contact: N. Blondeel 02/764 42 14

 

An open-label, multicenter, dose escalation, phase IB study with expansion phase to investigate the safety, pharmacokinetics, pharmacodynamics and therapeutic activity of emactuzumab and RO7009789 administrered in combination in patients with advanced solid tumors

Partie I : escalation phase : sein triple négatif, ovaire, pancréas, estomac, colorectal, mélanome, mésothéliome.

Partie II : expansion phase : colorectal, mélanome, BP29427

Sponsor: /

Principal Investigator:  Prof. JP.Machiels

Contact:V.Decroës 02/764 42 30

 

A phase Ib, open-label, multi-center study to chracterize the safety, tolerability and pharmacodynamics (PD) of PDR001 in combination with CJM112, EGF816, ILARIS(canakimumab) or Mekinist( trametinib) : TNBC/NSCLC- adenocarcinoma- CRC. PDR001X2103

Sponsor: /

Principal Investigator:  Prof. JP.Machiels

 

A Phase II Study of Palbociclib plus Fulvestrant versus Placebo plus Fulvestrant for pretreated patients with ER+/HER2- Metastatic Breast Cancer. Palbociclib in molecularly characterized ER-positive/HER2-negative metastatic breast cancer: the PYTHIA study. BIG 14-04 – Pythia

Sponsor: /

Principal Investigator: Prof. F. Duhoux

Contact: N. Blondeel / E. Villar 02/764 42 14

 

A phase iii, multicenter, randomized, placebo-controlled study of atezolizumab (anti−pd-l1 antibody) in combination with nab-paclitaxel compared with placebo with nab-paclitaxel for patients with previously untreated metastatic triple-negative breast cancer. IMPassion WO29522

Sponsor: Roche

Principal Investigator: Prof. F. Duhoux

Contact: N. Blondeel 02/764 42 14

 

HER2+

 

A Study of Neratinib plus Capecitabine in patients with HER2+ metastatic breast cancer who have received two or more prior HER2-directed regimens in the metastatic setting. NALA-PUMA

Sponsor: /
Principal Investigator: Prof. F. Duhoux
Contact: N. Blondeel 02/764 42 14

 

A Randomized, Multicenter, Open Label Study of MM-302 plus Trastuzumab vs. Chemotherapy of Physician's Choice plus Trastuzumab in Anthracycline Naive Patients with Locally Advanced/Metastatic HER2-Positive Breast Cancer. Hermione

Sponsor: /
Principal Investigator: Prof. F. Duhoux
Contact: N. Blondeel 02/764 42 14 

 

A MULTICENTER, OPEN-LABEL, SINGLE-ARM SAFETY STUDY OF HERCEPTIN® SC IN COMBINATION WITH PERJETA® AND DOCETAXEL IN TREATMENT OF PATIENTS WITH HER2 POSITIVE ADVANCED BREAST CANCER (METASTATIC OR LOCALLY RECURRENT). COVANCE – BO29159

Sponsor: Covance

Principal Investigator: Prof. F. Duhoux

Contact: N. Blondeel 02/764 42 14


A phase 3, randomized study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the treatment of patients with HER2+ Metastatic Breast cancer who have received two prior anti HER2 therapies and require systemic treatment. Macrogenics - Sophia

Sponsor: /
Principal Investigator: Prof. JF. Baurain
Contact: N. Blondeel 02/764 42 14 

 

ER+

 

A phase I/Ib, open-label stydy of LSZ102 single agent and LSZ102 in combination  with either LEE011(LSZ102+LEE011) or BYL 719(LSZ102+BYL719 )in patients with advanced or metastatic ER+breast cancer who have progressed after endocrine therapy. CLSZ102X2101

Sponsor: /

Principal Investigator: Prof. F. Duhoux

Contact: B. Vanderelst 02/764 42 99

 

_________________________________________________________

 

Tumeurs du système nerveux central

 

A randomized , placebo controlled Phase 2/3 study ABT414 with concurrent chemoradiation and adjuvant temozolomide in subjects with newly diagnosised glioblastoma(GBM) with epidermal growth factor receptor ( EGFR) amplification ( intellance1)  Abbvie M13-813

Sponsor: /

Principal Investigator: Dr. N. Whenham

Contact: ML. Castella 02/764 54 27

 

A Randomized Phase 3 Open Label Study of Nivolumab vs Temozolomide Each in Combination with Radiation Therapy in Newly Diagnosed Adult Subjects with Unmethylated MGMT (tumor O-6-methylguanine DNA methyltransferase) Glioblastoma. CA209-498

Sponsor: /

Principal Investigator: Dr. N. Whenham

Contact: ML. Castella 02/764 54 27

 

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6-methylguanine DNA methyltransferase) Glioblastoma. CA209-548

Sponsor: /

Principal Investigator: Dr. N. Whenham

Contact: ML. Castella 02/764 54 27

_________________________________________________________

 

Tumeurs endocrines et de la glande thyroïde

 

 

_________________________________________________________

 

Tumeurs gynécologiques pelviennes

 

A phase III trial of postoperative chemotherapy or no further treatment for patients with node negative stage I-II intermediate or high risk endometrial cancer. ENGOT

Sponsor: /
Principal Investigator: Prof. JF. Baurain
Contact:  E. Carrie 02/764 54 66

 

A randomized phase III trial comparing radical hysterectomy and pelvic node dissection vs simple hysterectomy and pelvic node dissection in patients with low-risk early-stage cervical cancer. BGOG-CX2/shape
Sponsor: /
Principal Investigator: Prof. JF. Baurain
Contact: E. Carrie 02/764 54 66

 

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy and Safety of Farletuzumab (MORAb-003) in Combination with Carboplatin plus Paclitaxel or Carboplatin plus Pegylated Liposomal Doxorubicin (PLD) in Subjects with Low CA125 Platinum-Sensitive Ovarian Cancer. MORAB
Sponsor: /
Principal Investigator: Prof. JF. Baurain
Contact: E. Carrie 02/764 54 66

 

A phase 2, randomized study of MLN0128 (a dual TORC1/2 inhibitor), MLN0128 + MLN1117 (a PI3Kα inhibitor), weekly paclitaxel, or the combination of weekly paclitaxel and MLN0128 in women with advanced, recurrent, or persistent endometrial cancer. TAKEDA

Sponsor: /

Principal Investigator: Prof. JF. Baurain

Contact: E. Carrie 02/764 54 66

 

p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246. PISARRO

Sponsor: /

Principal Investigator: Prof. JF. Baurain

Contact: E. Carrie 02/764 54 66

 

A non-interventional Belgian study to collect data on the safety and efficacy of frontline Bevacizumab treatment in ovarian cancer patients ≥ 70 years. BELOVA

Sponsor: /

Principal Investigator: Prof. JF. Baurain

Contact: E. Carrie 02/764 54 66

 

Phase 3 Maintenance Study to Evaluate the Efficacy and Safety of Niraparib Versus Placebo in women who have not progressed after first line chemotherapy for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. PRIMA

Sponsor: /

Principal Investigator: Prof. JF. Baurain

Contact: E. Carrie 02/764 54 66

 

An open-label, multi-center, dose escalation phase I study of single agent RO5520985(vanucizumab) and in combinaison with atezolizumab, administered as an intravenous infusion in patients with locally advanced or metastatic solid tumors: Ovaire-trompe-peritoine primitif. BP28179

Sponsor: /

Principal Investigator:  Prof. JP.Machiels

Contact:V.Decroës 02/764 42 30 

 

First-human, dose-escalating safety study of tissue factor specific antibody drug conjugate (HUMAX®-TF-ADC) in patient with locally advanced and/or metastatic solid tumors known to express tissue factor: Col / endomètre / ovaire (waiting list) / vessie /prostate / poumon / œsophage + ORL . GEN701

Sponsor: /

Principal Investigator: Prof. JP.Machiels

Contact:I. Beaufay 02/764 42 04

 

A phase I/IIa study of BMS 986148, a mesothelin directed antibody drug conjugate, in subjects with selected advanced solid tumors: cancer du pancréas, cancer des ovaires, cancer du poumon non à petites cellules [CPNPC], cancer de l’estomac ou mésothéliome. CA008-002

Sponsor: /

Principal Investigator:  Prof. JP.Machiels

Contact: C. Szablonski 02/764 42 21

_________________________________________________________

 

Tumeurs hépato-bilio-pancréatiques


Hepatocellular Carcinoma and Cholangiocarcinoma

 

Multicentre, Randomised, Controlled, Open-label study comparing the efficacy and safety of slow repeated intravenous infusions of 2 doses of Doxorubicin Transdrug? (DT) (20mg/m² and 30mg/m² to those of best supportive care (BSC) in patients suffering from advanced hepatocellular carcinoma (HCC) after failure or intolerance to sorafenib.BA2011/03/04

Sponsor: Relive

Principal Investigator: Dr. I. Borbat

Contact: T. Le 02/764 42 13


Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ramucirumab and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (AFP) Following First-Line Therapy With Sorafenib. REACH-2

Sponsor: /

Principal Investigator: Dr. I. Borbat

Contact: T. Le 02/764 42 13


A phase II study of Pembrolizumab (MK-3475) as Monotherapy in Subjects with Previously Systemically Treated Advanced Hepatocellular Carcinoma – 2d line. KEYNOTE-224

Sponsor: /

Principal Investigator: Dr. I. Borbat

Contact: T. Le 02/764 42 13


A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications : melanome/HCC ( 2d ligne ou sorafenib intolérant)/NSCLC. EMR200647-001

Sponsor: /

Principal Investigator: Prof. JP.Machiels

Contact:I. Beaufay 02/764 42 04


Pancreatic and Advanced Neuro-Endocrine pancreatic tumor Cancer

 

A European, multicentre, phase II/III randomised double-blind, placebo controlled study evaluating lanreotide as maintenance therapy in patients with non-resectable duodeno-pancreatic neuroendocrine tumours after first-line treatment. REMINET

Sponsor: /

Principal Investigator: Dr. I. Borbat

Contact: T. Le 02/764 42 13

 

Sandostatin (Octreotide LAR) may lead to Clinical Improvement through Receptor OCCupation Optimisation. A prospective interventional trial of patients with neuro-endocrine tumors with carcinoid syndrome receiving octreotide LAR. SCIROCCO

Sponsor: /

Principal Investigator: Dr. I. Borbat

Contact: T. Le 02/764 42 13

 

An open-label, multicenter, dose escalation, phase IB study with expansion phase to investigate the safety, pharmacokinetics, pharmacodynamics and therapeutic activity of emactuzumab and RO7009789 administrered in combination in patients with advanced solid tumors

Partie I : escalation phase : sein triple négatif, ovaire, pancréas, estomac, colorectal, mélanome, mésothéliome.

Partie II : expansion phase : colorectal, mélanome, BP29427

 

A phase I/IIa study of BMS 986148, a mesothelin directed antibody drug conjugate, in subjects with selected advanced solid tumors: cancer du pancréas, cancer des ovaires, cancer du poumon non à petites cellules [CPNPC], cancer de l’estomac ou mésothéliome. CA008-002

Sponsor: /

Principal Investigator:  Prof. JP.Machiels

Contact: C. Szablonski 02/764 42 21

 

A randomized, multicenter, double-blind, placebo-controlled, Phase 2/3 study of the Bruton Tyrosine Kinase inhibitor ibrutinib in combination with nab-paclitaxel and gemcitabine versus placebo in combination with nab-paclitaxel and gemcitabine, in the first line treatment of patients with metastatic pancreatic adenocarcinoma. RESOLVE

Sponsor: /

Principal Investigator: Prof. M. van den Eynde

Contact: T. Le 02/764 42 13

 

Carcinoid Tumors


A randomized phase II double-blind trial of sunitinib versus placebo in combination with lanreotide in patients with progressive advanced/metastatic midgut carcinoïd tumors.D12-01 SUNLAND
Sponsor: /
Principal Investigator: Dr. I. Borbath
Contact: T. Le 02/764 42 13

 

_________________________________________________________

 

Tumeurs thoraciques et pulmonaires

 

Tumeurs pulmonaires (Non-small cell lung cancer + Small cell lung cancer)


Phase III, Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of MPDL3280A (anti-PD-L1 Antibody) in Combination with Carboplatin + Nab-Paclitaxel for Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer-. GO29537

Sponsor: /
Principal Investigator: Prof. X. Geets
Contact: V. Erculisse 02/764 24 67

 

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy and Safety of MPDL3280A (anti-PD-L1 Antibody) in Combination with Carboplatin + Paclitaxel or MPDL3280A in Combination with Carboplatin + Nab-Paclitaxel Versus Carboplatin + Nab-Paclitaxel in Chemotherapy-Naïve Patients with Stage IV Squamous Non-Small Cell Lung Cancer-. GO29437

Sponsor: /
Principal Investigator: Prof. Ph. Collard
Contact: V. Erculisse 02/764 24 67

(Ouverture septembre 2015)


LungTech Stereotactic Body Radiotherapy (SBRT) of inoperable centrally located NSCLC: A phase II study in preparation for a randomized phase III trial. LungTech
Sponsor:/
Principal Investigator: Prof.X. Geets
Contact: V. Erculisse 02/764 24 67

 

A Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, following Complete Tumour Resection With or Without Adjuvant Chemotherapy. ADAURA

Sponsor: /

Principal Investigator: Prof. Th.Pieters

Contact: V. Erculisse 02/764 24 67

 

An Open-label, Randomized, Phase 3 Study of Nivolumab or Chemotherapy in Subjects with Relapsed Small-cell Lung Cancer after Platinum-based First Line Chemotherapy. CA209-331

Sponsor: /

Principal Investigator: Prof. Th.Pieters

Contact: V. Erculisse 02/764 24 67

 

A phase III, open label, randomized study to investigate the efficacy and safety of MPDL3280A (Anti-PD-L1 Antibody) therapy compared with standard of care following adjuvant cisplatin-based chemotherapy in PDL-1 selected patients with completely resected Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC). GO29527

Sponsor: /

Principal Investigator: Prof. Ph. Collard

Contact: V. Erculisse 02/764 24 67

 

EGFR mutation analysis in non-small-cell-lung cancer using a liquid biopsy ? concordance between ctDNA and formalin fixed paraffin embedded (FFPE) material analysis ? real time follow up of resistance / response to anti-EGFR therapy. 

Sponsor: /

Principal Investigator: Prof. Th.Pieters

Contact: V. Erculisse 02/764 24 67

 

A randomized, open-label, active-controlled, Phase II study of intravenous anetumab ravtansine (BAY 94-9343) or vinorelbine in patients with advanced or metastatic malignant pleural mesothelioma overexpressing mesothelin and progressed on first line platinum/pemetrexed-based chemotherapy. 15743

Sponsor: /

Principal Investigator: Prof. Th.Pieters

Contact: V. Erculisse 02/764 24 67

 

A phase Ib/II, open-label, multicenter trial with oral cMET inhibitor INC280 alone and in combination with erlotinib versus platinum/pemetrexed in adult patients with EGFR mutated, cMET-amplified, locally advanced/metastatic non small cell lung cancer (NSCLC) with acquired resistance to prior EGFR tyrosine kinase inhibitor (EGFR TKI). CINC280B2201

Sponsor: /

Principal Investigator: Prof. Th.Pieters

Contact: V. Erculisse 02/764 24 67

 

Double blind, randomised, multicentre, phase II/III study of nintedanib in combination with pemetrexed/cisplatin followed by continuing nintedanib monotherapy versus placebo in combination with pemetrexed/cisplatin followed by continuing placebo monotherapy for the treatment of patients with unresectable malignant pleural mesothelioma (MPM). 1199.33

Sponsor: /

Principal Investigator: Prof. Th.Pieters

Contact: V. Erculisse 02/764 24 67

 

A Phase 2, Randomized, Double-Blind Study of Veliparib in Combination with Carboplatin and Etoposide as a Therapy of Treatment Naïve Extensive Stage Small. Cell Lung Cancer

Sponsor: /

Principal Investigator: Prof. Y. Humblet

Contact: V. Erculisse 02/764 24 67

 

First-human, dose-escalating safety study of tissue factor specific antibody drug conjugate (HUMAX®-TF-ADC) in patient with locally advanced and/or metastatic solid tumors known to express tissue factor : GEN701

Sponsor: /

Principal Investigator: Prof. JP.Machiels

Contact:I. Beaufay 02/764 42 04

 

A single Arm, multicenter, phase 1b study with an expansion cohort to evaluate safety and efficacy of necitumumab in combination with abemaciclib in treatment of Patients with stage IV non-small cell lung cancer (NSCLC). I4X-MC-JFCU

Sponsor: /

Principal Investigator:  Prof. JP.Machiels

Contact: B. Vanderelst 02/764 42 99

 

An open-label, multicenter, dose escalation, phase IB study with expansion phase to investigate the safety, pharmacokinetics, pharmacodynamics and therapeutic activity of emactuzumab and RO7009789 administrered in combination in patients with advanced solid tumors

Partie I : escalation phase : sein triple négatif, ovaire, pancréas, estomac, colorectal, mélanome, mésothéliome.

Partie II : expansion phase : colorectal, mélanome, BP29427

Sponsor: /

Principal Investigator:  Prof. JP.Machiels

Contact:V.Decroës 02/764 42 30 

 

A phase I/IIa study of BMS 986148, a mesothelin directed antibody drug conjugate, in subjects with selected advanced solid tumors : cancer du pancréas, cancer des ovaires, cancer du poumon non à petites cellules [CPNPC], cancer de l’estomac ou mésothéliome. CA008-002

Sponsor: /

Principal Investigator:  Prof. JP.Machiels

Contact: C. Szablonski 02/764 42 21

 

A phase Ib, open-label, multi-center study to chracterize the safety, tolerability and pharmacodynamics (PD) of PDR001 in combination with CJM112, EGF816, ILARIS(canakimumab) or Mekinist( trametinib) : TNBC/NSCLC- adenocarcinoma- CRC. PDR001X2103

Sponsor: /

Principal Investigator: Prof. JP.Machiels

 

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications : melanome/HCC/NSCLC( 2de ligne après platine-EGFR+ non eligible OU 3 ème ligne après platine et antiPD1-PDL1 en monothérapie. EMR200647-001

Sponsor: /

Principal Investigator: Prof. JP.Machiels

Contact:I. Beaufay 02/764 42 04

_________________________________________________________

 

 Etudes de Phase I

 

Non- comparative, two cohort, single arm, open-label, phase 1/2 study of nivolumab (BMS-936558) in subjects with virus-positive and virus -negative solid tumors (ouverture le 09/09/2015) 

- Néo-adjuvante (2cures de Nivo) : SCCHN (HPV+ et -), GYN (col, vulve, vagin), Merkel 

- Adjuvante : reste : SCCHN HPV +, Estomac EBV + . CA209-358

Sponsor: / 

Principal Investigator: Prof. JP. Machiels
Contact: V. Decröes 02/764 42 30

 

First-human, dose-escalating safety study of tissue factor specific antibody drug conjugate (HUMAX®-TF-ADC) in patient with locally advanced and/or metastatic solid tumors known to express tissue factor : GEN701

Sponsor: /

Principal Investigator: Prof. JP.Machiels

Contact:I. Beaufay 02/764 42 04

 

A phase I, open-label, multi-centre, multi-dose, dose escalation study of LTX-315 as monotheraoy or in combination with either ipilimumab or pembrolizumab, in patients with transdermally accessible tumours. C12-315-03
Sponsor:Lytix biopharma

Principal Investigator: Prof. JF.Baurain
Contact: B.Vanderelst 02/764 42 99

 

An open-label, multicenter, dose escalation, phase IB study with expansion phase to investigate the safety, pharmacokinetics, pharmacodynamics and therapeutic activity of emactuzumab and RO7009789 administrered in combination in patients with advanced solid tumors

Partie I : escalation phase : sein triple négatif, ovaire, pancréas, estomac, colorectal, mélanome, mésothéliome.

Partie II : expansion phase : colorectal, mélanome, BP29427

Sponsor: /

Principal Investigator:  Prof. JP.Machiels

Contact:V.Decroës 02/764 42 30 

 

A phase I/IIa study of BMS 986148, a mesothelin directed antibody drug conjugate, in subjects with selected advanced solid tumors : cancer du pancréas, cancer des ovaires, cancer du poumon non à petites cellules [CPNPC], cancer de l’estomac ou mésothéliome. CA008-002

Sponsor: /

Principal Investigator:  Prof. JP.Machiels

Contact: C. Szablonski 02/764 42 21

 

An open-label, non-randomised, multicentre, comparative, phase I study to determine the pharmacokinetics, safety and tolerability of AZD9291(anti-EGFR)following a single oral dose to patients with advanced solid tumours and normal hepatic function or mild or moderate hepatic impairment 

Hepatic impairment : cirrhosis from any origin but not due to metastasis and Hepatitis B and C are excluded -> mostly from alcohol origin. D5160C00008

Sponsor: /

Principal Investigator: Prof. J.P. Machiels

Contact: B.Vanderelst 02/764 42 99

 

A phase I/Ib, open-label stydy of LSZ102 single agent and LSZ102 in combination  with either LEE011(LSZ102+LEE011) or BYL 719(LSZ102+BYL719 )in patients with advanced or metastatic ER+breast cancer who have progressed after endocrine therapy. CLSZ102X2101

Sponsor: /

Principal Investigator: Prof. F. Duhoux

Contact: B. Vanderelst 02/764 42 99

 

A single Arm, multicenter, phase 1b study with an expansion cohort to evaluate safety and efficacy of necitumumab in combination with abemaciclib in treatment of Patients with stage IV non-small cell lung cancer (NSCLC). I4X-MC-JFCU

Sponsor: /

Principal Investigator:  Prof. JP.Machiels

Contact: B. Vanderelst 02/764 42 99

 

A phase 1a/1b , multi center, open-label, dose finding study to assess the safety, tolerability, pharmacokinetics and prileminary efficacy of the pleiiotropic pathway modifier cc-122 administered orally to subjects with advanced solid tumors, non-hodgkin's lymphoma or multuple myeloma cc-122 : potent immunomodulator (thalidomide like). 2 cohorts available in St Luc : Lymphoma DLBCL and Myelomes multiples. Celgene

Sponsor: /
Principal Investigator: Prof. JP. Machiels
Contact: A. Moxhon 02/764 42 17

 

An open-label, multi-center, dose escalation phase I study of single agent RO5520985(vanucizumab) and in combinaison with atezolizumab, administered as an intravenous infusion in patients with locally advanced or metastatic solid tumors: Ovaire-trompe-peritoine primitif. BP28179

Sponsor: /

Principal Investigator:  Prof. JP.Machiels

Contact:V.Decroës 02/764 42 30 

 

A phase Ib, open-label, multi-center study to chracterize the safety, tolerability and pharmacodynamics (PD) of PDR001 in combination with CJM112, EGF816, ILARIS(canakimumab) or Mekinist( trametinib) : TNBC/NSCLC- adenocarcinoma- CRC. PDR001X2103

Sponsor: /

Principal Investigator:  Prof. JP.Machiels

Contact: B. Vanderelst 02/764 42 99

 

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications : melanome/HCC ( 2d ligne ou sorafenib intolérant)/NSCLC. EMR200647-001

Sponsor: /

Principal Investigator: Prof. JP.Machiels

Contact:I. Beaufay 02/764 42 04

(cohorte pancréas et colon déjà fermée au recrutement)

 

A multicentre, Phase IIb, randomised, double blind, placebo-controlled study in hormone receptor-positive metastatic breast carcinoma patients receiving IMP321 (LAG-3Ig fusion protein) or placebo as adjunctive to a standard chemotherapy treatment regimen of paclitaxel. AIPAC (Active Immunotherapy PAClitaxel)

Sponsor: /

Principal Investigator:  Prof. JP. Machiels

Contact:V.Decroës 02/764 42 30 

 

A single Arm, multicenter, phase 1b study with an expansion cohort to evaluate safety and efficacy of necitumumab in combination with abemaciclib in treatment of Patients with stage IV non-small cell lung cancer (NSCLC). Lilly-JFCU

Sponsor: Lilly

Principal Investigator:  Prof. JP.Machiels

Contact: B. Vanderelst 02/764 42 99

 

 

Nos Experts

Découvrez les experts de l’Institut Roi Albert II.

Les types de tumeurs




L’Institut Roi Albert II est membre de l'OECI

Regarder nos dernières vidéos 

Cliniques Universitaires St-Luc, Av Hippocrate, 10 - 1200 Bruxelles - Belgique | Tél: 02/764 11 11 | FAX: 02/764 37 03 | Plan d'accès

2019 Institut Roi Albert II, Cliniques Universitaires St-Luc  -  Crédit photos - © Clin.univ.St-Luc / H. Depasse